Clinical Trial Update: Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Becotatug Vedotin (MRG003) in combination with a PD-1 blocker and chemoradiotherapy for high-risk locoregionally advanced nasopharyngea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer
• Nasopharyngeal Carcinoma

Drugs mentioned

• Becotatug Vedotin

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Status: NOT_YET_RECRUITING